Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 17, Number 8—August 2011

Research

Novel Arenavirus Infection in Humans, United States

Mary Louise Milazzo, Grant L. Campbell, and Charles F. FulhorstComments to Author 
Author affiliations: Author affiliations: University of Texas Medical Branch, Galveston, Texas, USA (M.L. Milazzo, C.F. Fulhorst); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (G.L. Campbell)

Main Article

Table 3

Antibody (immunoglobulin G) against WWAV and LCMV in paired serum samples from humans with acute central nervous system disease or undifferentiated febrile illnesses, United States*

Case-patient no.
Age, y, at illness onset
Days after illness onset
Antibody titer, WWAV
Antibody titer, LCMV Apparent
homologous virus
S1
S2
S1
S2
S1
S2
1 32 14 44 <320 640 <320 <320 WWAV
2 65 15 61 <320 2,560 <320 <320 WWAV
3 38 14 33 <320 <320 5,120 5,120 LCMV
4 51 2 68 <320 <320 320 20,480 LCMV
5 59 24 38 <320 <320 320 5,120 LCMV
6 72 0 15 <320 <320 <320 640 LCMV
7 12 25 33 <320 <320 320 320 Indeterminate
8 25 47 123 <320 <320 320 320 Indeterminate

*WWAV, Whitewater Arroyo virus; LCMV, lymphocytic choriomeningitis virus; S1, first sample; S2, second (last) sample in paired samples.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO